Department of Urology, Ludwig-Maximilians-University, Munich, Germany.
Department of Urology, Clinic of Korneuburg, Korneuburg, Austria.
Urology. 2015 Feb;85(2):316-20. doi: 10.1016/j.urology.2014.10.019.
To evaluate prospectively the efficacy and the safety of the ArgusT in male patients with persistent stress urinary incontinence.
A prospective 2-center evaluation was conducted on consecutive patients treated for persistent stress incontinence. Forty-two patients were implanted with the ArgusT male sling system with no associated surgery. Measurements included daily pad usage, 24-hour pad weight test, International Quality of Life questionnaire, International Consultation on Incontinence Questionnaire short form, and the Patient Global Impression of Improvement. Postoperative complications were assessed using the Clavien-Dindo classification. The definitions used were cured, 0-5 g in 24-hour pad weight test; improved, reduction of urine loss in 24-hour pad weight test >50%; and failed, all others.
After a mean follow-up of 28.8 months (20-38 months), 26 patients were dry (61.9%) with a pad test of 0-5 g/24 hours. Eleven patients (26.2%) improved. Five patients are considered failures. Overall daily pad use, urine loss in the 24-hour pad test, and quality of life scores improved significantly after sling implantation. Median adjustment rate was 1.7. There were no perioperative complications. Postoperative complications were mainly grade I and II complications according to the Clavien-Dindo classification.
The ArgusT sling system offers an effective and safe treatment option for male patients with moderate to severe stress urinary incontinence in a follow-up >2 years, even after radiotherapy.
前瞻性评估 ArgusT 在男性持续性压力性尿失禁患者中的疗效和安全性。
对连续接受治疗的持续性压力性尿失禁患者进行前瞻性 2 中心评估。42 例患者植入 ArgusT 男性吊带系统，无相关手术。测量包括日常垫使用量、24 小时垫重试验、生活质量问卷、国际尿失禁咨询问卷短表和患者整体改善印象。使用 Clavien-Dindo 分类评估术后并发症。使用的定义为：治愈，24 小时垫重试验中 0-5g；改善，24 小时垫重试验中尿失减少>50%；失败，所有其他情况。
平均随访 28.8 个月（20-38 个月）后，26 例患者（61.9%）干燥，垫重试验为 0-5g/24 小时。11 例（26.2%）患者改善。5 例患者被认为失败。吊带植入后，总体日常垫使用量、24 小时垫尿失量和生活质量评分均显著改善。中位数调整率为 1.7。无围手术期并发症。术后并发症主要为 Clavien-Dindo 分类的 I 级和 II 级并发症。
ArgusT 吊带系统为中重度压力性尿失禁男性患者提供了一种有效且安全的治疗选择，随访时间超过 2 年，甚至在放疗后也是如此。
